Clinical trials: Primary Cancer of the Peritoneum
Ovarian Cancer
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215
- Trial name
- NCT07532148
- Testing
- CKD-215, D215
- Volunteers
- 24 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Ovarian Cancer, Fallopian Tube Cancer
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study
The purpose of this study is to explore the experiences of Black women who receive care for ovarian cancer at Memorial Sloan Kettering Cancer Center, or "MSK" for short.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02928549
- Testing
- semi-structured interviews
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Gynecologic Cancer
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care.
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- OLIGYNE-10 RT (NCT07883798)
- Testing
- Routine-care metastasis-directed radiotherapy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT06483048
- Testing
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03552471
- Testing
- Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer, Malignant Tumor of Peritoneum
Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer
RATIONALE: Quality-of-life assessment in patients undergoing cancer treatment may help determine the intermediate- and long-term effects of the treatment on these patients.
- Conditions
- Ovarian Cancer, Malignant Tumor of Peritoneum, Quality of Life
- Trial name
- NCT00004909
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma
- Trial name
- POSITION (NCT02316834)
- Testing
- Laboratory Biomarker Analysis, BMN 673
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with…
- Trial name
- NCT03642132
- Testing
- Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020696
- Testing
- cisplatin, tirapazamine
- Where
- 54 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
The Treatment Preferences of Women Diagnosed With Ovarian Cancer
The primary objective of this study is to apply best-practice stated-preference methods to quantify the extent to which women with ovarian cancer accept the risks, side effects, and out-of-pocket costs associated with treatment…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT03367260
- Testing
- Preference Elicitation
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Duke University
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
This phase I/II trial tests the safety, side effects and best dose of a combination therapy (niraparib and selenium) in treating patients with BRCA negative ovarian cancer that has come back (recurrent) and does not respond to…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05672095
- Testing
- Biopsy, Biospecimen Collection, Niraparib
- Sponsor
- City of Hope Medical Center
Platinum-sensitive Relapsed Ovarian Cancer
Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient
This is a 2:1 randomized, double-blind, placebo-controlled, multi-center, phase III clinical study evaluating the efficacy and safety of ZL-2306 (niraparib) for maintenance treatment in patients with platinum-sensitive relapsed…
- Trial name
- NCT03705156
- Testing
- ZL-2306(nirapairb)
- Where
- 27 sites in China
- Volunteers
- 265 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT01137071
- Testing
- Monoclonal antibody Hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 29 people
- Sponsor
- Recepta Biopharma
Advanced Ovarian Cancer
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.
- Trial name
- ROLANDO (NCT03161132)
- Testing
- Olaparib, Pegylated Liposomal Doxorubicin
- Where
- 8 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Fallopian Tube Cancer, Peritoneal Cavity Cancer
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT01281514
- Testing
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I trial studies the side effects and best way to give metformin hydrochloride, carboplatin, and paclitaxel in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT02050009
- Testing
- metformin hydrochloride, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7
- Trial name
- NCT02042430
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cancer
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02278783
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Ovarian Cancer, Primary Peritoneal Cancer
Phase II ABT-888 With Cyclophosphamide
Background: The experimental cancer treatment drug ABT-888 (Veliparib) works by preventing deoxyribonucleic acid (DNA) repair in tumor cells.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer
- Trial name
- NCT01306032
- Testing
- ABT-888, Cyclophosphamide
- Where
- 10 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms, Ovarian Cancer
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens.
- Trial name
- QUADRA (NCT02354586)
- Testing
- Niraparib
- Where
- 55 sites in United States, Canada
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.